Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
MWN-AI** Summary
Lonza's Synaffix B.V. and Sidewinder Therapeutics recently announced a significant multi-target licensing agreement aimed at advancing the development of next-generation bispecific antibody-drug conjugates (ADCs) for treating solid tumors. This collaboration leverages Lonza's clinically validated ADC platform and Sidewinder’s innovative bispecific ADC pipeline, enhancing therapeutic indices while minimizing damage to healthy tissue.
Under the terms of the agreement, Sidewinder will utilize Lonza's proprietary technologies, including GlycoConnect® for antibody conjugation, HydraSpace® polar spacer technology, and toxSYN® linker payloads. In return, Lonza will receive upfront and milestone payments, along with royalties on net sales of developed products. Lonza will handle the manufacturing of components linked to its technologies, while Sidewinder will oversee research, development, and commercialization.
Peter van de Sande, Head of Synaffix at Lonza, expressed confidence in the partnership, suggesting that the integration of their platforms could significantly enhance tumor targeting capabilities in ADCs, potentially leading to life-saving therapies for cancer patients. Similarly, Eric Murphy, CEO of Sidewinder Therapeutics, emphasized that the collaboration reflects a pivotal moment in ADC innovation, where novel technologies could reshape cancer treatments by improving tolerability.
Both companies aim to initiate a clinical trial for a first-in-class bispecific ADC by 2026, marking a critical step in the evolution of precision oncology. Synaffix, fully acquired by Lonza in mid-2023, specializes in ADC technology, while Sidewinder, founded in 2023 and backed by OrbiMed, focuses on developing advanced therapeutics that specifically target tumor complexes. This partnership represents a promising convergence of cutting-edge biotechnological advancements in the fight against cancer.
MWN-AI** Analysis
The recent multi-target licensing agreement between Lonza's Synaffix and Sidewinder Therapeutics signifies a strategic move with promising implications for the biotech landscape, particularly in solid tumor treatments. This partnership not only highlights the growing importance of antibody-drug conjugates (ADCs) but also illustrates the potential for innovation in targeted cancer therapies.
Lonza, a heavyweight in the pharmaceutical manufacturing sector, is leveraging its clinically validated ADC platform, which includes cutting-edge technologies like GlycoConnect® and toxSYN®. These assets are expected to enhance Sidewinder’s pipeline of bispecific ADCs, which aim for improved selectivity and efficacy against solid tumors. This collaboration sets a robust foundation for developing next-generation therapies that could reshape patient treatment paradigms.
From an investment perspective, Lonza (SWX: LONN) presents a strong case for growth. The company not only stands to gain from upfront and milestone payments but can also capitalize on royalties from successful product sales. As clinical trials progress—Sidewinder plans to initiate a trial in 2026—investors should monitor the landscape for both technological advancements and potential disruptions in the ADC market.
Additionally, the collaboration aligns with broader industry trends emphasizing precision medicine, which investors find increasingly attractive. Both companies are operating in a strongly innovation-driven biotech ecosystem that is witnessing increased investor interest and funding, particularly for companies developing unique therapeutic approaches.
Overall, investors should maintain a bullish outlook on Lonza, while keeping a close watch on Sidewinder Therapeutics. As both companies advance their pipeline and product development, their joint efforts may yield significant competitive advantages and improved market positioning in the booming ADC space. Engaging with their stocks could provide opportunities for capital appreciation as they journey toward regulatory approvals and commercialization.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications
AMSTERDAM and SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Sidewinder Therapeutics, a precision ADC therapeutics company with a pipeline of bispecific antibodies with enhanced tumor-cell specificity and internalization, today announced that they have entered into a multi-target licensing agreement to develop first-in-class bispecific ADC therapeutics to treat solid tumor indications.
Through the agreement, Sidewinder gains access to Lonza's clinically validated, site-specific ADC technology platform including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and a toxSYN® linker payload. Under the terms of the agreement, Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Lonza is responsible for manufacturing components that are related to its proprietary technologies, and Sidewinder is responsible for the research, development, manufacturing, and commercialization of the ADCs.
Peter van de Sande, Head of Synaffix at Lonza, commented:
"This collaboration brings together two cutting-edge platforms to enhance the therapeutic index of bispecific ADCs by minimizing impact on healthy tissue. We are confident that our technologies will help Sidewinder's pipeline reach its full potential in maximizing tumor targeting, hence delivering new life-saving therapies for the benefit of patients with cancer."
Eric Murphy, PhD, Co–Founder and Chief Executive Officer of Sidewinder Therapeutics, said:
"The ADC field has reached an exciting moment fueled by multiple technology breakthroughs that enable the next generation of bispecific ADC innovation. Sidewinder's bispecific antibody approach targeting tumor-specific receptor complexes combined with Synaffix's clinically validated site-specific linker-payload platform creates an ideal synergy with the potential to greatly impact patient benefit. This collaboration advances our mission to reshape the cancer treatment landscape by improving tolerability for bispecific ADCs."
About Lonza
Lonza is one of the world's largest development and manufacturing organizations (CDMOs). Working across five continents, our global team of more than 19,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Our company generated sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in Half-Year 2025. Find out more at www.lonza.com.
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.
The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its partner pipeline.
Synaffix was fully acquired by Lonza in June 2023.
About Sidewinder Therapeutics
Sidewinder Therapeutics is a biotechnology company developing next generation large molecule precision therapeutics using bispecific ADCs designed to expand the therapeutic window by targeting tumor-specific complexes to enhance specificity and internalization. Sidewinder has partnered with Lonza to apply Synaffix's site-specific linker-payload platform across multiple programs. Sidewinder expects to initiate a clinical trial for a first-in-class bispecific ADC in 2026. The company was founded in 2023 with a Series A investment from OrbiMed and is headquartered in San Diego, CA. For more information, visit www.sidewinderbio.com.
SOURCE Synaffix
FAQ**
How does the multi-target license agreement between Lonza Group AG ADR LZAGY and Sidewinder Therapeutics enhance the potential for developing first-in-class bispecific ADCs for solid tumors?
What specific advantages do Lonza's GlycoConnect®, HydraSpace®, and toxSYN® technologies offer in the development of ADCs, according to the agreement with Sidewinder Therapeutics and Lonza Group AG ADR LZAGY?
With Sidewinder Therapeutics gaining access to Lonza’s ADC platform through the agreement, what milestones and royalty structures should investors in Lonza Group AG ADR LZAGY expect as development progresses?
What are the potential implications of this collaboration between Lonza Group AG ADR LZAGY and Sidewinder for the future landscape of cancer treatment and patient benefits?
**MWN-AI FAQ is based on asking OpenAI questions about Lonza Group AG ADR (OTC: LZAGY).
NASDAQ: LZAGY
LZAGY Trading
-1.32% G/L:
$60.9975 Last:
60,301 Volume:
$61.47 Open:
